Cookie Hinweis

Wir verwenden Cookies, um Ihnen ein optimales Webseiten-Erlebnis zu bieten. Dazu zählen Cookies, die für den Betrieb der Seite notwendig sind, sowie solche, die lediglich zu anonymen Statistikzwecken, für Komforteinstellungen oder zur Anzeige personalisierter Inhalte genutzt werden. Sie können selbst entscheiden, welche Kategorien Sie zulassen möchten. Bitte beachten Sie, dass auf Basis Ihrer Einstellungen womöglich nicht mehr alle Funktionalitäten der Seite zur Verfügung stehen. Weitere Informationen finden Sie in unseren Datenschutzhinweisen .

Essentiell

Diese Cookies sind für die Funktionalität unserer Website erforderlich und können nicht deaktiviert werden.

Name Webedition CMS
Zweck Dieses Cookie wird vom CMS (Content Management System) Webedition für die unverwechselbare Identifizierung eines Anwenders gesetzt. Es bietet dem Anwender bessere Bedienerführung, z.B. Speicherung von Sucheinstellungen oder Formulardaten. Typischerweise wird dieses Cookie beim Schließen des Browsers gelöscht.
Name econda
Zweck Session-Cookie für die Webanalyse Software econda. Diese läuft im Modus „Anonymisiertes Messen“.
Statistik

Diese Cookies helfen uns zu verstehen, wie Besucher mit unserer Webseite interagieren, indem Informationen anonym gesammelt und analysiert werden. Je nach Tool werden ein oder mehrere Cookies des Anbieters gesetzt.

Name econda
Zweck Measure with Visitor Cookie emos_jcvid
Externe Medien

Inhalte von externen Medienplattformen werden standardmäßig blockiert. Wenn Cookies von externen Medien akzeptiert werden, bedarf der Zugriff auf diese Inhalte keiner manuellen Zustimmung mehr.

Name YouTube
Zweck Zeige YouTube Inhalte
Name Twitter
Zweck Twitter Feeds aktivieren

Communication channels in the brain

No. 13 | 22/03/2012 | by Koh

Jakob von Engelhardt leads a new Junior Research Group, “Synaptic Communication and Neurodegeneration”, established by the German Center for NeurodegenerativeDiseases (DZNE) at the German Cancer Research Center (DKFZ) with the aim of combining the competencies of the two institutes. Research topics of the group include the cellular foundations of learning and memory as well as the molecular causes of neurodegenerative diseases.

Jakob von Engelhardt
© Brigitte Engelhardt, Deutsches Krebsforschungszentrum

In the brain, a number of receptors for the glutamate neurotransmitter play a key role: They mediate communication between neurons and, thus, also control essential brain functions such as learning and memory. The receptors are protein channels located on the membranes of neuronal cells which bind glutamate and, as a result, open up to let sodium, potassium or calcium enter the cells. With his newly established working group, Dr. Jakob von Engelhardt will investigate, among other things, the role of these receptors in the pathogenesis of dementia caused by Alzheimer’s disease. Plaques made up of a protein called amyloid beta are believed to be among the causes of the destruction of the central nervous system in Alzheimer’s patients. However, scientists have come to the conclusion that it is not the insoluble plaques that cause the pathogenic changes but rather their precursors, soluble aggregates (“oligomers”) of amyloid beta molecules. Von Engelhardt’s group pursues studies with genetically engineered mice to find out whether such amyloid-beta oligomers interact with glutamate receptors and may thus exert their cytopathic effect.

A second focus of von Engelhardt’s research is the fine tuning of a certain type of glutamate receptor called AMPA receptor. The neuroscientist is studying the question of which proteins come into contact with the receptor and how this happens. These interactions determine the number, localization and function of AMPA receptors in the synapse and are therefore crucial for many cognitive processes.

Thirty-nine-year-old Jakob von Engelhardt studied medicine and started his neuroscience career at the University Hospital of Neurology in Heidelberg, where he pursued research at the Department of Clinical Neurobiology headed by Professor Hannah Monyer. In 2010, the department was turned into a collaborative department of Heidelberg University and DKFZ.

The German Center for Neurodegenerative Diseases (DZNE) was established in 2009 in the Helmholtz Association as the first of six German Centers for Health Research founded by the Federal Ministry for Education and Research. The DZNE comprises research groups based at nine sites across Germany. Jakob von Engelhardt leads the joint Junior Research Group of DKFZ and DZNE. The group is based at DKFZ in Heidelberg in order to collaboratively use highly specialized infrastructure such as for electrophysiological measuring methods and to combine competencies in the field of neuroscience.

A picture of Jakob von Engelhardt is available under:
http://www.dkfz.de/de/presse/pressemitteilungen/2012/images/Jakob-von-Engelhardt.jpg

Source: Brigitte Engelhardt, Deutsches Krebsforschungszentrum

With more than 3,000 employees, the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) is Germany’s largest biomedical research institute. DKFZ scientists identify cancer risk factors, investigate how cancer progresses and develop new cancer prevention strategies. They are also developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to questions relating to cancer.

To transfer promising approaches from cancer research to the clinic and thus improve the prognosis of cancer patients, the DKFZ cooperates with excellent research institutions and university hospitals throughout Germany:

  • National Center for Tumor Diseases (NCT, 6 sites)
  • German Cancer Consortium (DKTK, 8 sites)
  • Hopp Children's Cancer Center (KiTZ) Heidelberg
  • Helmholtz Institute for Translational Oncology (HI-TRON Mainz) - A Helmholtz Institute of the DKFZ
  • DKFZ-Hector Cancer Institute at the University Medical Center Mannheim
  • National Cancer Prevention Center (jointly with German Cancer Aid)
The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.

RSS-Feed

Subscribe to our RSS-Feed.

to top
powered by webEdition CMS